Refine by
Prostate Cancer Suppliers & Manufacturers
86 companies found
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
based inTehran, IRAN
Pars Isotope Co is a prominent supplier and producer of radioisotopes in Iran, catering widely to the medical and industrial sectors. As the sole provider in the region, the company focuses on radiopharmaceuticals used for both the diagnosis and ...
Lu-177-PSMA is a theranostic radiopharmaceutical designed for the treatment of metastatic prostate cancer. Employing the Peptide Receptor Radionuclide Therapy (PRRT) technique, it selectively targets and binds to ...
based inLausanne, SWITZERLAND
Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to improve patient outcomes and quality of life in oncology and bacterial infections. Our main activities include drug development, drug ...
Triptorelin decreases the serum testosterone to castrate levels (estradiol in females). Androgen deprivation stops the growth of the androgen dependent prostate cancer, alleviating pain and improving thus the ...
based inBethlehem, PENNSYLVANIA (USA)
OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. Together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, OraSure provides its ...
For detection and monitoring of cancers, as well as new biomarker development, a larger volume of urine can be required. Additionally, Colli-Pee® Large Volumes supports multi-omics research. Collector tubes can be pre-filled with a preservative ...
based inWoodinville, WASHINGTON (USA)
Cancer Targeted Technology is designing and patenting small molecular weight enzyme inhibitors with unique and exceptional imaging and drug delivery properties. Cancer Targeted Technology (CTT) develops innovative targeted agents for cancer that ...
CTT’s lead therapeutic product, CTT1403, is a PSMA-targeted 177Lu-labeled agent for prostate cancer that can has superior binding characteristics, long circulation half-life, enhanced tumor uptake and ...
based inSolna, SWEDEN
Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® ...
Docetaxel micellar is a product candidate in early clinical development and is a novel formulation that combines XR-17 with docetaxel - a well-established cytotoxin, currently administered intravenously and containing ethanol. In June 2020, Vivesto ...
based inGarching / Munich, GERMANY
ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes ...
based inSan Diego, CALIFORNIA (USA)
Decipher, a part of Veracyte, offers genomic tests for urologic cancers. Decipher Biosciences offers a portfolio of genomic tests, continues to build the GRID database of over 70,000 whole transcriptome profiles, and is partnering with ...
Using Decipher genomic testing to determine where a patient is within the spectrum of risk empowers you in personalizing patient ...
based inReno, NEVADA (USA)
DxDiscovery is a biotechnology Research & Development firm. The corporate goal is to develop quality, high-affinity antibodies to microbial antigens. These antibodies are incorporated into rapid POC diagnostics, or they may be developed as ...
based inWaltham, MASSACHUSETTS (USA)
Exosome Diagnostics, Inc. is commercializing minimally invasive molecular diagnostics in blood and urine to enable doctors to select optimal therapies for cancer and other diseases. Exosomes are lipid bilayer covered microvesicles shed by solid ...
The only exosome-based test that provides unique, actionable intelligence to help you decide if biopsy is necessary; independent of PSA and other standard of care (SOC) features. Connect with a representative in your area for more information ...
based inKvistgaard, DENMARK
Pnn Medical A/S was established in 1987 to improve the quality of life for people suffering from urinary tract obstructions. Since launch more than 90.000 units of the second-generation urological stent Memokath™ have been inserted worldwide and ...
Memokath™ 028 Prostate is a non-allergenic metallic stent used to effectively treat prostatic obstruction without the side-effects of major surgery, or discomfort of catheters. Memokath™ 028 Prostate is a non-allergenic metallic stent ...
based inMelbourne, AUSTRALIA
Starpharma Holdings Limited is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for COVID-19, DEP drug delivery and ...
DEP® radiotheranostic conjugates have the potential to minimise off-target toxicity, optimise pharmacokinetics and enhance efficacy when used alone or in combination with other therapeutic approaches. The versatility of Starpharma’s ...
based inCarlton South, AUSTRALIA
Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease ...
CHM 1101 (CLTX CAR T) is an optimized first-in-class CAR T cell therapy that uniquely utilizes Chlorotoxin (CLTX), a 36-amino acid peptide derived from deathstalker scorpion venom as its tumour targeting ...
based inPlymouth, MASSACHUSETTS (USA)
We started Medical Monofilament in 1999 in order to produce the best sensory testing monofilament available. Our goal was and still is to help decrease the incidence of diabetic foot ulcerations and amputations for diabetic patients at risk. For ...
based inKøbenhavn N, DENMARK
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor ...
based inEttlingen, GERMANY
We are a pioneering medical device company focused on transforming the lives of patients with difficult to treat cancers by applying our discoveries in bioelectromagnetics to targeted treatment of cancer. Our patient-based research using low and ...
based inSan Diego, CALIFORNIA (USA)
At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, ...
based inSan Diego, CALIFORNIA (USA)
Cortechs.ai is the leader in radiology AI applications, using cutting-edge advances in medical imaging to revolutionize disease screening and early detection so patients can enjoy longer, better lives. The company develops and markets breakthrough ...
OnQ Prostate is FDA-cleared post-processing software that supports improved detection of clinically significant prostate cancer. Leveraging an advanced diffusion MRI technique called Restriction ...
based inMiserey, FRANCE
Innovative Solutions for Cancer Diagnostics. OncoDiag is a French biotechnology company based in Normandy at one hour from Paris and Rouen cities. The company is focused on developing of non-invasive diagnostic tests for early detection of cancers. ...
An accurate tissue-based test to predict non-evolutive localized prostate cancer (LPCa). ...
based inOxford, UNITED KINGDOM
Blue Earth Diagnostics is an established molecular imaging company on a growth trajectory to provide innovative, well differentiated diagnostics solutions, informing patients and driving future therapies in cancer. Formed in 2014, Blue Earth ...
The targeting molecule delivers a therapeutic dose of radiation to kill tumour cells. Blue Earth Diagnostics acquired exclusive, worldwide rights to radiohybrid Prostate Specific Membrane Antigen (rhPSMA) targeted technology in ...